Curcumin is a powerful antioxidant and anti-inflammatory spice. Inflammation plays a role in many eye conditions, including uveitis, glaucoma, and macular degeneration. Used for millennia in Indian cooking, curcumin is the main ingredient in turmeric. Turmeric gives mustard its yellow color. When combined with black pepper, this spice is easier to absorb. You can use turmeric in cooking and take it as a supplement.
Uveitis Curcumin Study
Uveitis is inflammation of the uvea, the eye’s middle layer. Symptoms may include redness, floaters, sensitivity to light, Continue reading “Curcumin for Glaucoma, Uveitis, and Macular Degeneration”
Macular edema is a swelling of the macula, the part of the eye responsible for central vision. When fluid builds up in the macula, it becomes swollen and thicker. This distorts vision. There are several causes, including diabetic retinopathy, post-eye surgery complications, macular degeneration, injury, systemic inflammatory diseases that can affect the eye, and/or vein blockages. If an eye disease causes damage to blood vessels in the retina, it can cause macular edema. Left untreated, this problem can cause serious vision loss and even blindness.
Turmeric’s ability to support the body has been well-researched; however, this spice by itself is difficult for the body to absorb. This bright yellow spice is also called curcumin, and it contains a prized antioxidant. Research is verifying 
Research on turmeric spice indicates its potential to fight depression, cancer, diabetes, and neurodegenerative disease. The bright yellow spice, which lends color and flavor to mustard, curry, and other foods, also contains highly beneficial chemicals like curcumin.
Vitamin D
A pilot study published in Phytotherapy Research compared curcumin – derived from natural turmeric – with the drug diclofenac for treating rheumatoid arthritis (RA). Natural curcumin actually reduced RA symptoms even better than the RA drug diclofenac: a 44% reduction in symptoms on the Disease Activity Score and the American College of Rheumatology criteria for reduction of swelling and tenderness of joins. Patients receiving diclofenac had a 42% reduction.